{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:31:08Z","timestamp":1761183068349,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"am","delay-in-days":323,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jiac.2023.08.019","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T11:33:02Z","timestamp":1693567982000},"page":"12-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparing ceftolozane\/tazobactam versus piperacillin\/tazobactam for the initial empiric therapy of urinary tract infections: A retrospective comparative study"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2103-0834","authenticated-orcid":false,"given":"Tomomi","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Shigehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Shinzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yaegashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9792-2068","authenticated-orcid":false,"given":"Takahiro","family":"Nohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2023.08.019_bib1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/0970-1591.126900","article-title":"Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction","volume":"30","author":"Patel","year":"2014","journal-title":"Indian J Urol"},{"key":"10.1016\/j.jiac.2023.08.019_bib2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jiac.2021.06.006","article-title":"Complicated urinary tract infection in patients with benign prostatic hyperplasia","volume":"27","author":"Choi","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2023.08.019_bib3","first-page":"1","article-title":"Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden","volume":"28","author":"Foxman","year":"2014","journal-title":"Infect Dis Clin"},{"key":"10.1016\/j.jiac.2023.08.019_bib4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jiac.2023.08.019_bib5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/CMR.14.4.933-951.2001","article-title":"Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat","volume":"14","author":"Bradford","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiac.2023.08.019_bib6","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14822.1","article-title":"Treatment of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?","volume":"7","author":"Pana","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.jiac.2023.08.019_bib7","first-page":"825","article-title":"Ceftolozane\/Tazobactam: a new option in the treatment of complicated gram-negative infections","volume":"39","author":"Sorbera","year":"2014","journal-title":"P T"},{"key":"10.1016\/j.jiac.2023.08.019_bib8","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2023.08.019_bib9","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2023.08.019_bib10","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2023.08.019_bib11","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2023.08.019_bib12","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2023.08.019_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009\u20132010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jiac.2023.08.019_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4846159","article-title":"Isolation of extended-spectrum \u03b2-lactamase- (ESBL-) producing escherichia coli and klebsiella pneumoniae from patients with community-onset urinary tract infections in jimma university specialized hospital, southwest Ethiopia","volume":"2018","author":"Abayneh","year":"2018","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.jiac.2023.08.019_bib15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jmii.2013.08.006","article-title":"Epidemiology and risk factors of community-onset urinary tract infection caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in a medical center in Taiwan: a prospective cohort study","volume":"48","author":"Kung","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jiac.2023.08.019_bib16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jiac.2020.01.004","article-title":"The third national Japanese antimicrobial susceptibility pattern surveillance program: bacterial isolates from complicated urinary tract infection patients","volume":"26","author":"Kobayashi","year":"2020","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2023.08.019_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1639114","article-title":"A meta-analysis on clinical outcomes of ceftolozane versus piperacillin in combination with tazobactam in patients with complicated urinary tract infections","volume":"2022","author":"Saeed","year":"2022","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jiac.2023.08.019_bib18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1684-1182(10)60031-X","article-title":"Impact of extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections","volume":"43","author":"Yang","year":"2010","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jiac.2023.08.019_bib19","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijantimicag.2019.07.003","article-title":"Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: a systematic review, meta-analysis, and cost-effectiveness analysis","volume":"54","author":"Nguyen","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2023.08.019_bib20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jiac.2018.10.009","article-title":"The efficacy and safety of tazobactam\/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection","volume":"25","author":"Arakawa","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2023.08.019_bib21","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jiac.2021.07.022","article-title":"Catheter-associated urinary tract infection","volume":"27","author":"Chuang","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2023.08.019_bib22","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1442-2042.2009.02360.x","article-title":"Detection of drug-resistant Escherichia coli in patients with complicated cystitis: analysis of risk factors","volume":"16","author":"Shigehara","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.jiac.2023.08.019_bib23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jiac.2017.02.002","article-title":"H, arakawa S. JAID\/JSC Guidelines for clinical management of infectious disease 2015 - urinary tract infection\/male genital infection","volume":"23","author":"Yamamoto","year":"2017","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2023.08.019_bib24","article-title":"Clinical approach to nosocomial bacterial sepsis","volume":"13","author":"Reddy","year":"2021","journal-title":"Cureus"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23002052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23002052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:06:37Z","timestamp":1761159997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X23002052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1341321X23002052"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2023.08.019","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing ceftolozane\/tazobactam versus piperacillin\/tazobactam for the initial empiric therapy of urinary tract infections: A retrospective comparative study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2023.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}